D053628Chemicals & DrugsD12.776.543.750.705.852.610440.998622Receptors, Thrombopoietinprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson26951227Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally ACancer discoveryMutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81.Cancer Discov2016-03-07T00:00:002016Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.29288169Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally ABloodDefining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018 02 15; 131(7):782-786.Blood2017-12-29T00:00:002017Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.32694616Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SAModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncChronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.Mod Pathol2020-07-21T00:00:002020Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.Medicine-Hematology and Oncology0.1933780.008562824research area of0.774580.03429868subject area for35763665Jutzi JS, Marneth AE, Ciboddo M, Guerra-Moreno A, Jiménez-Santos MJ, Kosmidou A, Dressman JW, Liang H, Hamel R, Lozano P, Rumi E, Doench JG, Gotlib J, Krishnan A, Elf S, Al-Shahrour F, Mullally ABloodWhole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022 09 15; 140(11):1291-1304.Blood2022-09-15T00:00:002022Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.MedicinePathologyUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorSandeepGurbuxaniSandeep Gurbuxani41.78927490000000-87.601250000000002442Gurbuxani, SandeepProfessortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor23994117Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BLThe Journal of molecular diagnostics : JMDDetection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn. 2013 Nov; 15(6):810-8.J Mol Diagn2013-08-28T00:00:002013Detection of MPL mutations by a novel allele-specific PCR-based strategy.DanielArberDaniel Arber0.000000000000000.000000000000003406Arber, DanielProfessor